BioMotiv
Accelerating Breakthrough Discoveries into Medicines

News

News

BioMotiv & PharmaLex Establish Preferred Partnership

PharmaLex Group, one of the largest and most successful specialist providers of Development Consulting, Regulatory Affairs, Quality Management & Compliance and Pharmacovigilance, Epidemiology and Risk Management worldwide, has entered into a preferred partnership with BioMotiv, a mission-driven accelerator that advances breakthrough discoveries from research institutions into therapeutics for patients.

Read More
Erin Reese
SapVax Achieves Technical Milestone, Raises Additional Funding, and Expands Advisory Board

SapVax, a BioMotiv portfolio company developing a suite of cancer vaccines based on novel self-adjuvanting peptide technology, has achieved a significant proof-of-principle milestone, expanded its Scientific Advisory Board, and closed a new round of equity financing to continue to advance its unique platform towards the clinic.

Read More